← Leaderboards
Pasi A Janne
Stanford University
$27,388,753
Attributed
$35,042,990
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,042,990 · 12
By mechanism
R01$15,179,312 · 5
U01$7,338,262 · 1
R35$7,206,974 · 1
P01$3,289,335 · 2
P50$2,029,107 · 3
Top collaborators
- Nathanael Schiander Gray15 shared
- Bruce E. Johnson5 shared
- Levi Alexander Garraway4 shared
- Eliezer M Van Allen2 shared
- Nikhil Wagle2 shared
Most similar at Stanford University
Same institution · by research overlap
- Heike Elizabeth Daldrup-Link$23,256,656
- Thomas C Merigan$8,107,440
- Jia Wei Tan$81,364
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorCancer PatientMutationNon-Small-Cell Lung CarcinomaResistanceMalignant Neoplasm Of LungEpidermal Growth Factor ReceptorBaseSignal TransductionResistance MechanismClinical TrialsMutantEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorIn VivoIn VitroKinase InhibitorSignal PathwayInhibitor/AntagonistDrug ResistancePreventGenomicsTherapeutic TargetPre-Clinical Model
Grant awards (69)
Project 3$371,024
P50 · FY2025 · CA · contact PI
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance$995,148
R35 · FY2024 · CA · contact PI
Project 3$387,707
P50 · FY2024 · CA · contact PI
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance$1,026,576
R35 · FY2023 · CA · contact PI
Project 3$378,753
P50 · FY2023 · CA · contact PI
Targeting ALK through Degradation and Allosteric Inhibitors$257,105
R01 · FY2023 · CA
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance$1,026,576
R35 · FY2022 · CA · contact PI
Project 3$400,742
P50 · FY2022 · CA · contact PI
Resistance and Sensitivity to MET Inhibitors in Lung Cancer$382,595
R01 · FY2022 · CA · contact PI
Targeting ALK through Degradation and Allosteric Inhibitors$168,336
R01 · FY2022 · CA
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance$1,047,525
R35 · FY2021 · CA · contact PI
Resistance and Sensitivity to MET Inhibitors in Lung Cancer$390,403
R01 · FY2021 · CA · contact PI
Project 1: Development of pharmacologic strategies to degrade mutant EGFR.$287,962
P01 · FY2021 · CA · contact PI
Targeting ALK through Degradation and Allosteric Inhibitors$199,385
R01 · FY2021 · CA
Targeting ALK through Degradation and Allosteric Inhibitors$173,887
R01 · FY2021 · CA
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance$1,047,525
R35 · FY2020 · CA · contact PI
Resistance and Sensitivity to MET Inhibitors in Lung Cancer$390,403
R01 · FY2020 · CA · contact PI
Targeting ALK through Degradation and Allosteric Inhibitors$373,272
R01 · FY2020 · CA
Project 1: Development of pharmacologic strategies to degrade mutant EGFR.$287,962
P01 · FY2020 · CA · contact PI
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance$1,016,099
R35 · FY2019 · CA · contact PI
Resistance and Sensitivity to MET Inhibitors in Lung Cancer$378,690
R01 · FY2019 · CA · contact PI
Targeting ALK through Degradation and Allosteric Inhibitors$373,272
R01 · FY2019 · CA
Project 1: Development of pharmacologic strategies to degrade mutant EGFR.$287,962
P01 · FY2019 · CA · contact PI
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance$1,047,525
R35 · FY2018 · CA · contact PI
Resistance and Sensitivity to MET Inhibitors in Lung Cancer$390,403
R01 · FY2018 · CA · contact PI
Project 1: Development of pharmacologic strategies to degrade mutant EGFR.$287,962
P01 · FY2018 · CA · contact PI
Targeting RET in Lung Cancer$541,784
R01 · FY2017 · CA · contact PI
Drug Resistance in Lung Cancer$352,007
R01 · FY2017 · CA · contact PI
Targeting ALK and ROS1 in Lung Cancer$330,164
R01 · FY2017 · CA · contact PI
Project 1: Development of pharmacologic strategies to degrade mutant EGFR.$287,962
P01 · FY2017 · CA · contact PI
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$1,408,317
U01 · FY2016 · HG · contact PI
Targeting RET in Lung Cancer$541,784
R01 · FY2016 · CA · contact PI
EGFR Mutations in Non-Small Cell Lung Cancer$495,346
R01 · FY2016 · CA
Identification and Study of Novel EGFR Kinase Inhibtors$398,432
P01 · FY2016 · CA · contact PI
Drug Resistance in Lung Cancer$352,007
R01 · FY2016 · CA · contact PI
Targeting ALK and ROS1 in Lung Cancer$330,164
R01 · FY2016 · CA · contact PI
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$1,408,317
U01 · FY2015 · HG · contact PI
Targeting RET in Lung Cancer$541,784
R01 · FY2015 · CA · contact PI
EGFR Mutations in Non-Small Cell Lung Cancer$495,346
R01 · FY2015 · CA
Identification and Study of Novel EGFR Kinase Inhibtors$398,432
P01 · FY2015 · CA · contact PI
Drug Resistance in Lung Cancer$352,007
R01 · FY2015 · CA · contact PI
Targeting ALK and ROS1 in Lung Cancer$330,164
R01 · FY2015 · CA · contact PI
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$73,267
U01 · FY2015 · HG
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$1,470,233
U01 · FY2014 · HG
Targeting RET in Lung Cancer$525,531
R01 · FY2014 · CA · contact PI
EGFR Mutations in Non-Small Cell Lung Cancer$480,485
R01 · FY2014 · CA
Identification and Study of Novel EGFR Kinase Inhibtors$386,480
P01 · FY2014 · CA · contact PI
Drug Resistance in Lung Cancer$341,447
R01 · FY2014 · CA · contact PI
Targeting ALK and ROS1 in Lung Cancer$320,259
R01 · FY2014 · CA · contact PI
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$1,449,598
U01 · FY2013 · HG
Targeting RET in Lung Cancer$541,784
R01 · FY2013 · CA · contact PI
EGFR Mutations in Non-Small Cell Lung Cancer$465,626
R01 · FY2013 · CA
Drug Resistance in Lung Cancer$352,007
R01 · FY2013 · CA · contact PI
Targeting ALK and ROS1 in Lung Cancer$330,164
R01 · FY2013 · CA · contact PI
Identification and Study of Novel EGFR Kinase Inhibtors$236,605
P01 · FY2013 · CA · contact PI
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$1,528,530
U01 · FY2012 · HG
EGFR Mutations in Non-Small Cell Lung Cancer$495,415
R01 · FY2012 · CA
Identification and Study of Novel EGFR Kinase Inhibtors$429,576
P01 · FY2012 · CA · contact PI
Drug Resistance in Lung Cancer$348,207
R01 · FY2012 · CA · contact PI
EML4-ALK: A Potential Therapeutic Target in Lung Cancer$332,392
R01 · FY2012 · CA · contact PI
Drug Resistance in Lung Cancer$348,207
R01 · FY2011 · CA · contact PI
EML4-ALK: A Potential Therapeutic Target in Lung Cancer$342,364
R01 · FY2011 · CA · contact PI
EML4-ALK: A Potential Therapeutic Target in Lung Cancer$361,984
R01 · FY2010 · CA · contact PI
Drug Resistance in Lung Cancer$358,976
R01 · FY2010 · CA · contact PI
EML4-ALK: A Potential Therapeutic Target in Lung Cancer$376,204
R01 · FY2009 · CA · contact PI
Drug Resistance in Lung Cancer$358,976
R01 · FY2009 · CA · contact PI
Mechanisms of acquired resistance to EGFR-targeted agents$270,317
P50 · FY2009 · CA · contact PI
Drug Resistance in Lung Cancer$358,976
R01 · FY2008 · CA · contact PI
Mechanisms of acquired resistance to EGFR-targeted agents$220,564
P50 · FY2008 · CA · contact PI